{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:08:59Z","timestamp":1790338139283,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/nrcardio.2012.33","type":"journal-article","created":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T11:37:46Z","timestamp":1332243466000},"page":"276-285","source":"Crossref","is-referenced-by-count":44,"title":["Key advances in antihypertensive treatment"],"prefix":"10.1038","volume":"9","author":[{"given":"Ludovit","family":"Paulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike M.","family":"Steckelings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"issue":"Suppl. B","key":"BFnrcardio201233_CR1","doi-asserted-by":"publisher","first-page":"B13","DOI":"10.1093\/eurheartj\/sum003","volume":"9","author":"H Redwood","year":"2007","unstructured":"Redwood, H. Hypertension, society, and public policy. Eur. Heart. J. Suppl. 9 (Suppl. B), B13\u2013B18 (2007).","journal-title":"Eur. Heart. J. Suppl."},{"key":"BFnrcardio201233_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrcardio.2010.85","volume":"7","author":"L Paulis","year":"2010","unstructured":"Paulis, L. & Unger, T. Novel therapeutic targets for hypertension. Nat. Rev. Cardiol. 7, 431\u2013441 (2010).","journal-title":"Nat. Rev. Cardiol."},{"key":"BFnrcardio201233_CR3","unstructured":"Drugs@FDA: FDA Approved Drug Products. FDA US Food and Drug Administration \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrcardio201233_CR4","unstructured":"FDA Approved Drugs for Cardiology\/Vascular Diseases. Center Watch \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrcardio201233_CR5","unstructured":"New Medicines Database. PhRMA \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrcardio201233_CR6","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehr253","volume":"32","author":"T Unger","year":"2011","unstructured":"Unger, T., Paulis, L. & Sica, D. A. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur. Heart. J. 32, 2739\u20132747 (2011).","journal-title":"Eur. Heart. J."},{"key":"BFnrcardio201233_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2000","unstructured":"Dahl\u00f6f, B.  et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995\u20131003 (2000).","journal-title":"Lancet"},{"key":"BFnrcardio201233_CR8","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius, S.  et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022\u20132031 (2004).","journal-title":"Lancet"},{"key":"BFnrcardio201233_CR9","unstructured":"ONTARGET Investigators.  et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547\u20131559 (2008)."},{"key":"BFnrcardio201233_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","volume":"57","author":"WB White","year":"2011","unstructured":"White, W. B.  et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 57, 413\u2013420 (2011).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","volume":"13","author":"GL Bakris","year":"2011","unstructured":"Bakris, G. L.  et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J. Clin. Hypertens. (Greenwich) 13, 81\u201388 (2011).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"BFnrcardio201233_CR12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/hr.2009.135","volume":"32","author":"TW Kurtz","year":"2009","unstructured":"Kurtz, T. W. & Klein, U. Next generation multifunctional angiotensin receptor blockers. Hypertens. Res. 32, 826\u2013834 (2009).","journal-title":"Hypertens. Res."},{"key":"BFnrcardio201233_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"DA Lane","year":"2007","unstructured":"Lane, D. A., Shah, S. & Beevers, D. G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J. Hypertens. 25, 891\u2013894 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrcardio201233_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman, N.  et al. Effect of spironolactone on blood pressure in patients with resistant hypertension. Hypertension 49, 839\u2013845 (2007).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka, M. K., Zaman, M. A. & Calhoun, D. A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16, 925\u2013930 (2003).","journal-title":"Am. J. Hypertens."},{"key":"BFnrcardio201233_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger, M. H., Roniker, B., Krause. S. L. & Weiss, R. J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 15, 709\u2013716 (2002).","journal-title":"Am. J. Hypertens."},{"key":"BFnrcardio201233_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","volume":"150","author":"MH Weinberger","year":"2005","unstructured":"Weinberger, M. H.  et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am. Heart J. 150, 426\u2013433 (2005).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201233_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1517\/14656566.9.4.509","volume":"9","author":"A Karagiannis","year":"2008","unstructured":"Karagiannis, A.  et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin. Pharmacother. 9, 509\u2013515 (2008).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrcardio201233_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B.  et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201233_CR20","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt, B.  et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108, 1831\u20131838 (2003).","journal-title":"Circulation"},{"key":"BFnrcardio201233_CR21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B.  et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309\u20131321 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201233_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","volume":"46","author":"B Pitt","year":"2005","unstructured":"Pitt, B.  et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am. Coll. Cardiol. 46, 425\u2013431 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201233_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1751-7176.2010.00377.x","volume":"13","author":"DA Sica","year":"2011","unstructured":"Sica, D. A. & Flack, J. M. Treatment considerations with aldosterone receptor antagonists. J. Clin. Hypertens. (Greenwich) 13, 65\u201369 (2011).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"BFnrcardio201233_CR24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar, L.  et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56, 831\u2013838 (2010).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR25","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","volume":"124","author":"DA Calhoun","year":"2011","unstructured":"Calhoun, D. A.  et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 124, 1945\u20131955 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201233_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg, L. & Blaschke, T. Adherence to medication. N. Engl. J. Med. 353, 487\u2013497 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201233_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","volume":"10","author":"JW Funder","year":"2005","unstructured":"Funder, J. W. Mineralocorticoid receptors: distribution and activation. Heart Fail. Rev. 10, 15\u201322 (2005).","journal-title":"Heart Fail. Rev."},{"key":"BFnrcardio201233_CR28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","volume":"51","author":"JD Dietz","year":"2008","unstructured":"Dietz, J. D.  et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51, 742\u2013748 (2008).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR29","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1021\/jm1002827","volume":"53","author":"GB Arhancet","year":"2010","unstructured":"Arhancet, G. B.  et al. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J. Med. Chem. 53, 4300\u20134304 (2010).","journal-title":"J. Med. Chem."},{"key":"BFnrcardio201233_CR30","doi-asserted-by":"publisher","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","volume":"285","author":"J Fagart","year":"2010","unstructured":"Fagart, J.  et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem. 285, 29932\u201329940 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFnrcardio201233_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ejphar.2008.02.001","volume":"584","author":"O Akizuki","year":"2008","unstructured":"Akizuki, O.  et al. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur. J. Pharmacol. 584, 424\u2013434 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrcardio201233_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2008.12.041","volume":"605","author":"T Isaka","year":"2009","unstructured":"Isaka, T.  et al. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur. J. Pharmacol. 605, 49\u201352 (2009).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrcardio201233_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/01.fjc.0000197539.12685.f5","volume":"47","author":"K Imagawa","year":"2006","unstructured":"Imagawa, K.  et al. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J. Cardiovasc. Pharmacol. 47, 133\u2013138 (2006).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnrcardio201233_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1139\/y11-054","volume":"89","author":"KN Pandey","year":"2011","unstructured":"Pandey, K. N. Guanylyl cyclase \/ atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation. Can. J. Physiol. Pharmacol. 89, 557\u2013573 (2011).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"BFnrcardio201233_CR35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/cvr\/cvr319","volume":"93","author":"Y Li","year":"2012","unstructured":"Li, Y., Madiraju, P. & Anand-Srivastava, M. B. Knockdown of natriuretic peptide receptor-A enhances receptor C expression and signalling in vascular smooth muscle cells. Cardiovasc. Res. 93, 350\u2013359 (2012).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201233_CR36","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1210\/en.2008-1360","volume":"150","author":"K Sabrane","year":"2009","unstructured":"Sabrane, K., Kruse, M. N., Gazinski, A. & Kuhn, M. Chronic endothelium-dependent regulation of arterial blood pressure by atrial natriuretic peptide: role of nitric oxide and endothelin-1. Endocrinology 150, 2382\u20132387 (2009).","journal-title":"Endocrinology"},{"key":"BFnrcardio201233_CR37","unstructured":"Jordan, R.  et al. Phase 1 study of the novel A-type natriuretic receptor agonist, PL-3994, in healthy volunteers. Presented at the 12th scientific meeting of the Heart Failure Society of America."},{"key":"BFnrcardio201233_CR38","unstructured":"Sica, D., Jordan, R. & Fischkoff, S. A. Phase IIa study of the NPR-agonist, PL-3994, in healthy adult volunteers with controlled hypertension. Presented at the 13th scientific meeting of the Heart Failure Society of America."},{"key":"BFnrcardio201233_CR39","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/hy0202.103788","volume":"39","author":"JD Imig","year":"2007","unstructured":"Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C. & Hammock, B. D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690\u2013694 (2007).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR40","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/01.RES.87.11.992","volume":"87","author":"Z Yu","year":"2000","unstructured":"Yu, Z.  et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87, 992\u2013998 (2000).","journal-title":"Circ. Res."},{"key":"BFnrcardio201233_CR41","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1073\/pnas.261710799","volume":"99","author":"BB Davis","year":"2002","unstructured":"Davis, B. B.  et al. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl Acad. Sci. USA 99, 2222\u20132227 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio201233_CR42","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.bmcl.2010.12.042","volume":"21","author":"SK Anandan","year":"2010","unstructured":"Anandan, S. K.  et al. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg. Med. Chem. Lett. 21, 983\u2013988 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrcardio201233_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/ph2030217","volume":"2","author":"JD Imig","year":"2009","unstructured":"Imig, J. D., Carpenter, M. A. & Shaw, S. The soluble epoxide hydrolase inhibitor AR9281 decreases blood pressure, ameliorates renal injury and improves vascular function in hypertension. Pharmaceuticals 2, 217\u2013227 (2009).","journal-title":"Pharmaceuticals"},{"key":"BFnrcardio201233_CR44","doi-asserted-by":"publisher","unstructured":"Chen, D.  et al. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J. Clin. Pharmacol. \n                    http:\/\/dx.doi.org\/10.1177\/0091270010397049\n                    \n                  .","DOI":"10.1177\/0091270010397049"},{"key":"BFnrcardio201233_CR45","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","volume":"26","author":"UM Steckelings","year":"2005","unstructured":"Steckelings, U. M., Kaschina, E. & Unger, T. The AT2 receptor\u2014a matter of love and hate. Peptides 26, 1401\u20131409 (2005).","journal-title":"Peptides"},{"key":"BFnrcardio201233_CR46","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1021\/jm049715t","volume":"47","author":"Y Wan","year":"2004","unstructured":"Wan, Y.  et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 47, 5995\u20136008 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnrcardio201233_CR47","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1161\/CIRCULATIONAHA.108.784868","volume":"118","author":"E Kaschina","year":"2008","unstructured":"Kaschina, E.  et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin\u2013angiotensin system in myocardial infarction? Circulation 118, 2523\u20132532 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio201233_CR48","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.109.147843","volume":"55","author":"F Rompe","year":"2010","unstructured":"Rompe, F.  et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor \u03baB. Hypertension 55, 924\u2013931 (2010).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR49","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/HYPERTENSIONAHA.111.180158","volume":"59","author":"A Rehman","year":"2012","unstructured":"Rehman, A.  et al. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59, 291\u2013299 (2012).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR50","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1161\/HYPERTENSIONAHA.111.185496","volume":"59","author":"L Paulis","year":"2012","unstructured":"Paulis, L.  et al. Direct angiotensin II type 2 receptor stimulation in N\u03c9-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension 59, 485\u2013492 (2012).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR51","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/01.HYP.0000054215.71691.16","volume":"41","author":"DJ Campbell","year":"2003","unstructured":"Campbell, D. J. Vasopeptidase inhibition: a double-edged sword? Hypertension 41, 383\u2013389 (2003).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR52","first-page":"1414","volume":"2","author":"R Tabrizchi","year":"2001","unstructured":"Tabrizchi, R. Omapatrilat. Bristol-Myers Squibb. Curr. Opin. Investig. Drugs 2, 1414\u20131422 (2001).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrcardio201233_CR53","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer, M.  et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106, 920\u2013926 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio201233_CR54","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope, L. M., Dukat, A., B\u00f6hm, M., Lacourci\u00e8re, Y., Gong, J. & Lefkowitz, M. P. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 375, 1255\u20131266 (2010).","journal-title":"Lancet."},{"key":"BFnrcardio201233_CR55","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/sj.bjp.0707516","volume":"153","author":"NS Kirkby","year":"2008","unstructured":"Kirkby, N. S., Hadoke, P. W. F., Bagnall, A. J. & Webb, D. J. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br. J. Pharmacol. 153, 1105\u20131119 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrcardio201233_CR56","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.tips.2007.10.002","volume":"28","author":"N Dhaun","year":"2007","unstructured":"Dhaun, N., Pollock, D. M., Goddard, J. & Webb, D. J. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol. Sci. 28, 573\u2013579 (2007).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrcardio201233_CR57","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/01.pap.0000249912.02763.65","volume":"14","author":"C Feldstein","year":"2007","unstructured":"Feldstein, C. & Romero, C. Role of endothelins in hypertension. Am. J. Therapeutics 14, 147\u2013153 (2007).","journal-title":"Am. J. Therapeutics"},{"key":"BFnrcardio201233_CR58","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","volume":"374","author":"MA Weber","year":"2009","unstructured":"Weber, M. A.  et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double blind, placebo-controlled trial. Lancet 374, 1423\u20131431 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio201233_CR59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","volume":"56","author":"GL Bakris","year":"2010","unstructured":"Bakris, G. L.  et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 56, 824\u2013830 (2010).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR60","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/HYPERTENSIONAHA.108.117226","volume":"52","author":"DA Sica","year":"2008","unstructured":"Sica, D. A. Endothelin receptor antagonism: what does the future hold? Hypertension 52, 460\u2013461 (2008).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR61","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1161\/HYPERTENSIONAHA.110.160952","volume":"56","author":"DJ Webb","year":"2010","unstructured":"Webb, D. J. DORADO: Opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension 56, 806\u2013807 (2010).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR62","unstructured":"New Medical Therapies: Hypertension (High blood pressure) CenterWatch \n                    [online]\n                    \n                   (2011)."},{"key":"BFnrcardio201233_CR63","unstructured":"PS433540 (DARA compounds). EvaluatePharma\u00ae\n \n                    [online]\n                    \n                  , (2010)."},{"issue":"Suppl. 2","key":"BFnrcardio201233_CR64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/01.fjc.0000166208.12297.8d","volume":"44","author":"C Th\u00f6ne-Reinke","year":"2004","unstructured":"Th\u00f6ne-Reinke, C.  et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J. Cardiovasc. Pharmacol. 44 (Suppl. 2), 76\u201379 (2004).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnrcardio201233_CR65","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/01.HYP.0000039748.88581.A0","volume":"40","author":"DN M\u00fcller","year":"2002","unstructured":"M\u00fcller, D. N.  et al. Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 40, 840\u2013846 (2002).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.amjcard.2004.03.074","volume":"94","author":"K Dickstein","year":"2004","unstructured":"Dickstein, K.  et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am. J. Cardiol. 94, 237\u2013239 (2004).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio201233_CR67","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1179\/016164111X12881719352534","volume":"33","author":"C Wengenmayer","year":"2011","unstructured":"Wengenmayer, C.  et al. Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival. Neurol. Res. 33, 201\u2013207 (2011).","journal-title":"Neurol. Res."},{"key":"BFnrcardio201233_CR68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/VHRM.S9989","volume":"6","author":"R D\u00fcsing","year":"2010","unstructured":"D\u00fcsing, R. Optimizing blood pressure control through the use of fixed combinations. Vasc. Health Risk Manag. 6, 321\u2013325 (2010).","journal-title":"Vasc. Health Risk Manag."},{"key":"BFnrcardio201233_CR69","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia, G.  et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105\u20131187 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrcardio201233_CR70","first-page":"20","volume":"6","author":"K Kappert","year":"2008","unstructured":"Kappert, K., Kusserow, H. & Unger, T. The pharmacological rationale behind polypharmacy in heart failure. Heart Fail. Monit. 6, 20\u201327 (2008).","journal-title":"Heart Fail. Monit."},{"key":"BFnrcardio201233_CR71","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00003495-200262030-00003","volume":"62","author":"DA Sica","year":"2002","unstructured":"Sica, D. A. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62, 443\u2013462 (2002).","journal-title":"Drugs"},{"key":"BFnrcardio201233_CR72","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","volume":"29","author":"T Philipp","year":"2007","unstructured":"Philipp, T.  et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther. 29, 563\u2013580 (2007).","journal-title":"Clin. Ther."},{"key":"BFnrcardio201233_CR73","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0895-7061(99)00237-X","volume":"13","author":"PR Conlin","year":"2000","unstructured":"Conlin, P. R.  et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am. J. Hypertens. 13, 418\u2013426 (2000).","journal-title":"Am. J. Hypertens."},{"key":"BFnrcardio201233_CR74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clinthera.2007.01.007","volume":"29","author":"JL Pool","year":"2007","unstructured":"Pool, J. L.  et al. Comparison of valsartan\/hydrochlorothiazide combination therapy at doses up to 320\/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin. Ther. 29, 61\u201373 (2007).","journal-title":"Clin. Ther."},{"key":"BFnrcardio201233_CR75","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1185\/03007995.2010.534129","volume":"26","author":"F Zeng","year":"2010","unstructured":"Zeng, F., Patel, B. V., Andrews, L., Frech-Tamas, F. & Rudolph, A. E. Adherence and persistence of single-pill ARB\/CCB combination therapy compared to multiple-pill ARB\/CCB regimens. Curr. Med. Res. Opin. 26, 2877\u20132887 (2010).","journal-title":"Curr. Med. Res. Opin."},{"key":"BFnrcardio201233_CR76","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1185\/03007990902785845","volume":"25","author":"TW Littlejohn 3rd","year":"2009","unstructured":"Littlejohn, T. W. 3rd, Trenkwalder, P., Hollanders, G., Zhao, Y. & Liao, W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr. Med. Res. Opin. 25, 951\u2013959, 2009.","journal-title":"Curr. Med. Res. Opin."},{"key":"BFnrcardio201233_CR77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3810\/pgm.2011.11.2492","volume":"123","author":"SG Chrysant","year":"2011","unstructured":"Chrysant, S. G. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. Postgrad. Med. 123, 21\u201331 (2011).","journal-title":"Postgrad. Med."},{"key":"BFnrcardio201233_CR78","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","volume":"24","author":"HH Parving","year":"2009","unstructured":"Parving, H. H.  et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24, 1663\u20131671 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrcardio201233_CR79","unstructured":"Novartis. Novartis announces termination of ALTITUDE study with Rasilez\u00ae\/Tekturna\u00ae in high-risk patients with diabetes and renal impairment. Novartis Global \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrcardio201233_CR80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.109.131300","volume":"54","author":"DA Calhoun","year":"2009","unstructured":"Calhoun, D. A., Lacourci\u00e8re, Y., Chiang, Y. T. & Glazer, R. D. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 54, 32\u201339 (2009).","journal-title":"Hypertension"},{"key":"BFnrcardio201233_CR81","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2009","unstructured":"Jamerson, K.  et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417\u20132428 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201233_CR82","unstructured":"US National Library of Medicine. Clinical trials.gov \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrcardio201233_CR83","unstructured":"US National Library of Medicine. Clinical trials.gov \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrcardio201233_CR84","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"H Krum","year":"2009","unstructured":"Krum, H.  et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275\u20131281 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio201233_CR85","doi-asserted-by":"publisher","unstructured":"Krum, H.  et al. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur. Heart J. \n                    http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehq457\n                    \n                  .","DOI":"10.1093\/eurheartj\/ehq457"},{"key":"BFnrcardio201233_CR86","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.110.971580","volume":"123","author":"H Krum","year":"2011","unstructured":"Krum, H.  et al. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 123, 209\u2013215 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201233_CR87","doi-asserted-by":"crossref","unstructured":"Symplicity HTN-2 Investigators.  et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903\u20131909 (2010).","DOI":"10.1016\/S0140-6736(10)62039-9"},{"key":"BFnrcardio201233_CR88","doi-asserted-by":"crossref","unstructured":"Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57, 911\u2013917 (2011).","DOI":"10.1161\/HYPERTENSIONAHA.110.163014"},{"key":"BFnrcardio201233_CR89","first-page":"R353","volume":"238","author":"RL Kline","year":"1980","unstructured":"Kline, R. L. & Mercer, P. F. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am. J. Physiol. 238, R353\u2013R358 (1980).","journal-title":"Am. J. Physiol."},{"key":"BFnrcardio201233_CR90","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1152\/jappl.1972.33.5.649","volume":"33","author":"G Nomura","year":"1972","unstructured":"Nomura, G., Kurosaki, M., Takabatake, T., Kibe, Y. & Takeuchi, J. Reinnervation and renin release after unilateral renal denervation in the dog. J. Appl. Physiol. 33, 649\u2013655 (1972).","journal-title":"J. Appl. Physiol."},{"key":"BFnrcardio201233_CR91","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1525-1594.1987.tb02710.x","volume":"11","author":"GF DiBona","year":"1987","unstructured":"DiBona, G. F. Renal innervation and denervation: lessons from renal transplantation reconsidered. Artif. Organs 11, 457\u2013462 (1987).","journal-title":"Artif. Organs"},{"key":"BFnrcardio201233_CR92","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1042\/cs0870013","volume":"87","author":"JM Hansen","year":"1994","unstructured":"Hansen, J. M.  et al. The transplanted human kidney does not achieve functional reinnervation. Clin. Sci. (Lond). 87, 13\u201320 (1994).","journal-title":"Clin. Sci. (Lond)."},{"key":"BFnrcardio201233_CR93","first-page":"481","volume":"52","author":"C Stefanadis","year":"2011","unstructured":"Stefanadis, C. Renal denervation in resistant hypertension: radiofrequency ablation and chemical denervation. Hellenic J. Cardiol. 52, 481\u2013482 (2011).","journal-title":"Hellenic J. Cardiol."},{"key":"BFnrcardio201233_CR94","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/CRD.0b013e3181f87921","volume":"19","author":"MM Ng","year":"2011","unstructured":"Ng, M. M., Sica, D. A. & Frishman, W. H. Rheos: an implantable carotid sinus stimulation device for the nonpharmacologic treatment of resistant hypertension. Cardiol. Rev. 19, 52\u201357 (2011).","journal-title":"Cardiol. Rev."},{"key":"BFnrcardio201233_CR95","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jacc.2010.03.089","volume":"56","author":"IJ Scheffers","year":"2010","unstructured":"Scheffers, I. J.  et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J. Am. Coll. Cardiol. 56, 1254\u20131258 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201233_CR96","unstructured":"Schmidli, J. 4-year results of the Rheos\u00ae trial for control of intractable hypertension by carotid sinus baroreceptor stimulation. Presented at the 38th Annual Vascular and Endovascular Issues, Techniques and Horizons Symposium."},{"key":"BFnrcardio201233_CR97","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","volume":"58","author":"JD Bisognano","year":"2011","unstructured":"Bisognano, J. D.  et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J. Am. Coll. Cardiol. 58, 765\u2013773 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201233_CR98","unstructured":"Hasenfuss, G. 2nd generation baroreflex activation therapy and ongoing clinical trials. Presented at the European Society for Cardiology Congress."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2012.33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2012.33","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2012.33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:50:07Z","timestamp":1684468207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2012.33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFnrcardio201233"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2012.33","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]}}}